Selection of chronic lymphocytic leukemia binding peptides

Area of Science:

• Biotechnology
• Oncology
• Molecular Biology

Background:

• Developing targeted therapies for chronic lymphocytic leukemia (CLL) is crucial for improving patient outcomes.
• Cell-binding ligands are essential for both ex vivo gene therapy and in vivo drug delivery applications.
• Phage display libraries offer a powerful tool for identifying novel peptide ligands with specific cellular targets.

Purpose of the Study:

• To identify novel cell-binding peptides for ex vivo gene therapy.
• To discover ligands that specifically target chronic lymphocytic leukemia (CLL) cells for in vivo applications.
• To evaluate the potential of identified peptides in retargeting viral vectors for enhanced gene delivery.

Main Methods:

• Selection of 44 20-mer peptides from peptide-presenting phage libraries through panning against primary patient CLL cells.
• Assaying 29 selected peptides for cell binding specificity against CLL, B cells, T cells, and monocytes.
• Testing synthetic peptides for cell binding and functional retargeting of adenovirus for gene delivery.

Main Results:

• Eight peptides demonstrated binding to CLL, B cells, T cells, and monocytes.
• Twelve peptides bound specifically to CLL and B cells.
• Eight peptides exhibited CLL-specific binding.
• Synthetic peptides successfully bound cells and enhanced ex vivo gene delivery to CLL cells via adenovirus retargeting.

Conclusions:

• Phage display panning against primary cancer cells is an effective method for identifying lead cancer-targeting peptides.
• Identified peptides show promise for targeted drug and gene therapy in CLL.
• These findings support the development of novel peptide-based strategies for cancer treatment and diagnostics.